- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 626837, 6 pages
Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria
Asthma and Allergy Clinic, Children’s Clinic Randers, Dytmærsken 9, 8900 Randers, Denmark
Received 5 April 2013; Accepted 26 June 2013
Academic Editor: Fulvio Braido
Copyright © 2013 Ole D. Wolthers. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Bousquet, N. Khaltaev, A. A. Cruz et al., “Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen),” Allergy, vol. 63, supplement 86, pp. 8–160, 2008.
- J. Bousquet, P. Van Cauwenberge, and N. Khaltaev, “Allergic rhinitis and its impact on asthma,” Journal of Allergy and Clinical Immunology, vol. 108, no. 5, pp. S147–S334, 2001.
- J. Bousquet, I. Anstegui, G. Walter Canonica et al., “Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review,” Current Medical Research and Opinion, vol. 28, no. 1, pp. 131–139, 2012.
- C. Bachert, “The role of histamine in allergic disease: Re-appraisal of its inflammatory potential,” Allergy, vol. 57, no. 4, pp. 287–296, 2002.
- P. Lieberman, “The basics of histamine biology,” Annals of Allergy, Asthma and Immunology, vol. 106, supplement 2, pp. S2–S5, 2011.
- R. Corcóstegui, L. Labeaga, A. Innerárity, A. Berisa, and A. Orjales, “Preclinical pharmacology of bilastine, a new selective histamine H 1 receptor antagonist: receptor selectivity and in Vitro antihistaminic activity,” Drugs in R and D, vol. 6, no. 6, pp. 371–384, 2005.
- F. E. R. Simons and K. J. Simons, “Histamine and H1-antihistamines: celebrating a century of progress,” Journal of Allergy and Clinical Immunology, vol. 128, no. 6, pp. 1130–1150, 2011.
- R. Corcóstegui, L. Labeaga, A. Innerárity, A. Berisa, and A. Orjales, “In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist,” Drugs in R and D, vol. 7, no. 4, pp. 219–231, 2006.
- M. K. Church, “Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans,” Inflammation Research, vol. 60, no. 12, pp. 1107–1112, 2011.
- M. J. Hanley, P. Cancalon, W. W. Widmer, and D. J. Greenblatt, “The effect of grapefruit juice on drug disposition,” Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 3, pp. 267–286, 2011.
- N. Jauregizar, L. D. L. Fuente, M. L. Lucero, A. Sologuren, N. Leal, and M. Rodríguez, “Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H 1) Effect of Bilastine,” Clinical Pharmacokinetics, vol. 48, no. 8, pp. 543–554, 2009.
- G. M. Walsh, L. Annunziato, N. Frossard et al., “New insights into the second generation antihistamines,” Drugs, vol. 61, no. 2, pp. 207–236, 2001.
- F. Horak, P. Zieglmayer, R. Zieglmayer, and P. Lemell, “The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber,” Inflammation Research, vol. 59, no. 5, pp. 391–398, 2010.
- C. Bachert, P. Kuna, F. Sanquer et al., “Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients,” Allergy, vol. 64, no. 1, pp. 158–165, 2009.
- P. Kuna, C. Bachert, Z. Nowacki et al., “Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study,” Clinical and Experimental Allergy, vol. 39, no. 9, pp. 1338–1347, 2009.
- J. Sastre, J. Mullol, A. Valero, and R. Valiente, “Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis,” Current Medical Research and Opinion, vol. 28, no. 1, pp. 121–130, 2012.
- T. Zuberbier, A. Oanta, E. Bogacka et al., “Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study,” Allergy, vol. 65, no. 4, pp. 516–528, 2010.
- I. Dávila, J. Sastre, J. Mullol et al., “Effect of bilastine upon nasal obstruction,” Journal of Investigational Allergology & Clinical Immunology, vol. 21, supplement 3, pp. 2–8, 2011.
- J. Bartra, J. Mullol, J. Montoro et al., “Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis,” Journal of Investigational Allergology & Clinical Immunology, vol. 21, supplement 3, pp. 24–33, 2011.
- E. F. Juniper, “Measuring health-related quality of life in rhinitis,” Journal of Allergy and Clinical Immunology, vol. 99, no. 2, pp. S742–S749, 1997.
- K. Krause, A. Spohr, M. K. Church, T. Zuberbeier, and M. Maurer, “High-dose bilastine is effective in reducing temperature thresholds in cold contact urticaria,” in Proceedings of the International Food Allergy Conference, Abstract 62, Anaheim, Calif, USA, November 2012.
- B. Tyl, M. Kabbaj, S. Azzam et al., “Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of at thorough QT study (TQTS) with QT-concentration analysis,” Journal of Clinical Pharmacology, vol. 52, no. 6, pp. 893–903, 2012.
- F. Ridout, Z. Shamsi, R. Meadows, S. Johnson, and I. Hindmarch, “A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car,” Clinical Therapeutics, vol. 25, no. 5, pp. 1518–1538, 2003.
- A. Patat, D. Stubbs, C. Dunmore et al., “Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects,” European Journal of Clinical Pharmacology, vol. 48, no. 2, pp. 143–150, 1995.
- C. García-Gea, J. Martínez-Colomer, R. M. Antonijoan, R. Valiente, and M.-J. Barbanoj, “Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments,” Journal of Clinical Psychopharmacology, vol. 28, no. 6, pp. 675–685, 2008.
- S. Conen, E. L. Theunissen, A. C. M. Van Oers, R. Valiente, and J. G. Ramaekers, “Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers,” Journal of Psychopharmacology, vol. 25, no. 11, pp. 1517–1523, 2011.
- J. F. O'Hanlon and J. G. Ramaekers, “Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989–94,” Allergy, vol. 50, no. 3, pp. 234–242, 1995.
- A. Lundh, S. Sismondo, J. Lexchin, O. A. Busuioc, and L. Bero, “Industry sponsorship and research outcome,” Cochrane Database of Systematic Reviews, 2012.
- N. J. Carter, “Bilastine in allergic rhinitis and urticaria,” Drugs, vol. 72, no. 9, pp. 1257–1269, 2012.
- W. W. Carr, P. Ratner, U. Munzel et al., “Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis,” Allergy and Asthma Proceedings, vol. 33, no. 6, pp. 450–458, 2012.
- T. Zuberbier, C. Bindslev-Jensen, W. Canonica et al., “EAACI/GA2LEN/EDF guideline: management of urticaria,” Allergy, vol. 61, no. 3, pp. 321–331, 2006.